Page last updated: 2024-08-24

topotecan and busulfan

topotecan has been researched along with busulfan in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (57.89)29.6817
2010's6 (31.58)24.3611
2020's2 (10.53)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ1
Thigpen, T1
Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA1
Díaz, MA; González-Vicent, M; Lassaletta, A; Madero, L; Pérez-Martínez, A; Sevilla, J1
Aleman, A; Anderson, KO; Brown, J; Campagnaro, E; Cleeland, C; Giralt, S; Mendoza, F; Roden, L; Saliba, R; Weber, D1
du Bois, A; Gropp, M; Kimmig, R; Kuhn, W; Lück, HJ; Meier, W; Olbricht, S; Pfisterer, J; Reuss, A; Richter, B1
Markman, M1
Cree, IA; Gabriel, FG; Glaysher, S; Johnson, P; Knight, LA; Narayanan, A; Parker, K; Polak, M; Poole, M1
Bauer, F; Burdach, S; Filipiak-Pittroff, B; von Luettichau, I; Wawer, A1
Husseini, GA; Ibrahim, M; Sabouni, R1
Bogart, E; Chastagner, P; Cougnenc, O; Defachelles, AS; Ferry, I; Kolesnikov-Gauthier, H; Michon, J; Oudoux, A; Proust, S; Schleiermacher, G; Valteau-Couanet, D1
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S1
Badel, JN; Bogart, E; Corradini, N; Cougnenc, O; Courbon, F; Defachelles, AS; Deley, MCL; Gambart, M; Giraudet, AL; Kolesnikov-Gauthier, H; Oudoux, A; Rault, E; Schleiermacher, G; Sevrin, F; Valteau-Couanet, D1

Reviews

4 review(s) available for topotecan and busulfan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Pharmacokinetically guided administration of chemotherapeutic agents.
    Clinical pharmacokinetics, 2000, Volume: 39, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Carboplatin; Cisplatin; Etoposide; Fluorouracil; Humans; Topotecan

2000
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

2002
Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs).
    Current medicinal chemistry, 2017, Volume: 24, Issue:2

    Topics: Antineoplastic Agents; Busulfan; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Carriers; Fluorouracil; Humans; Nanoparticles; Organometallic Compounds; Organoplatinum Compounds; Polymers; Porosity; Succinates; Topotecan

2017

Trials

4 trial(s) available for topotecan and busulfan

ArticleYear
High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
    Journal of neuro-oncology, 2005, Volume: 71, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Supratentorial Neoplasms; Thiotepa; Topotecan; Transplantation, Autologous; Treatment Outcome

2005
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolog
    Gynecologic oncology, 2009, Volume: 114, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Topotecan

2009
Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
    Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:6

    Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Neoplasm Metastasis; Neuroblastoma; Risk Factors; Topotecan

2018
Phase II study of
    Pediatric blood & cancer, 2023, Volume: 70, Issue:11

    Topics: 3-Iodobenzylguanidine; Adolescent; Busulfan; Child; Child, Preschool; Chronic Disease; Humans; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Young Adult

2023

Other Studies

11 other study(ies) available for topotecan and busulfan

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
    International journal of oncology, 2003, Volume: 22, Issue:5

    Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53

2003
Symptom burden after autologous stem cell transplantation for multiple myeloma.
    Cancer, 2008, Apr-01, Volume: 112, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Remission Induction; Severity of Illness Index; Survival Rate; Thiotepa; Topotecan; Transplantation, Autologous; Tumor Burden

2008
Chemotherapy: Topotecan or treosulfan--that is the question.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis; Time Factors; Topotecan

2009
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
    British journal of cancer, 2010, Aug-24, Volume: 103, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan

2010
Escalating topotecan in combination with treosulfan has acceptable toxicity in advanced pediatric sarcomas.
    Pediatric hematology and oncology, 2013, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Sarcoma; Topotecan

2013
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
    Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221

    Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water

2022